{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"10.0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"2"}],"units":"Participants"}],"description":"Note: In Cohort 5, the response was observed in a rhabdoid tumor. Participant was erroneously enrolled in the Non-rhabdomyosarcoma soft tissue sarcoma cohort.","groups":[{"description":"Participants with ewing sarcoma","id":"OG000","title":"Cohort 1"},{"description":"Participants with non-rhabdomyosarcoma soft tissue sarcoma","id":"OG001","title":"Cohort 5"},{"description":"Participants with osteosarcoma.","id":"OG002","title":"Cohort 6"},{"description":"Participants with rhabdomyosarcoma","id":"OG003","title":"Cohort 7"},{"description":"Participants with wilms tumor","id":"OG004","title":"Cohort 8"},{"description":"Participants with other tumor types with documented PD-L1 expression.","id":"OG005","title":"Cohort 9"},{"description":"Participants with other tumor types without documented PD-L1 expression.","id":"OG006","title":"Cohort 10"},{"description":"Participants with rhabdoid tumor.","id":"OG007","title":"Cohort 11"}],"paramType":"NUMBER","populationDescription":"Included safety-evaluable population, defined as patients who received any amount of study drug.","reportingStatus":"POSTED","timeFrame":"Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)","title":"Percentage of Participants With an Objective Response (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Participants With Solid Tumors","type":"PRIMARY","unitOfMeasure":"Percentage"}